Quazepam

Quazepam
Clinical data
Trade names	Doral
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a684001
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth
ATC code	N05CD10 (WHO) ;
Legal status
Legal status	CA: Schedule IV; US: WARNINGSchedule IV;
Pharmacokinetic data
Bioavailability	29–35%
Metabolism	Liver
Elimination half-life	39 hours
Excretion	Kidney
Identifiers
	IUPAC name 7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepine-2-thione;
CAS Number	36735-22-5 ;
PubChem CID	4999;
IUPHAR/BPS	7288;
DrugBank	DB01589 ;
ChemSpider	4825 ;
UNII	JF8V0828ZI;
KEGG	D00457 ;
ChEMBL	ChEMBL1200472 ;
CompTox Dashboard (EPA)	DTXSID60190193 ;
ECHA InfoCard	100.048.329
Chemical and physical data
Formula	C17H11ClF4N2S
Molar mass	386.79 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC(F)(F)CN1C(=S)C/N=C(\c2cc(Cl)ccc12)c3ccccc3F;
	InChI InChI=1S/C17H11ClF4N2S/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2 ; Key:IKMPWMZBZSAONZ-UHFFFAOYSA-N ;
	(what is this?) (verify)

Quazepam, sold under brand name Doral among others, is a relatively long-acting benzodiazepine derivative drug developed by the Schering Corporation in the 1970s.^[2] Quazepam is used for the treatment of insomnia including sleep induction and sleep maintenance.^[3] Quazepam induces impairment of motor function and has relatively (and uniquely) selective hypnotic and anticonvulsant properties with considerably less overdose potential than other benzodiazepines (due to its novel receptor-subtype selectivity).^[4]^[5] Quazepam is an effective hypnotic which induces and maintains sleep without disruption of the sleep architecture.^[6]

It was patented in 1970 and came into medical use in 1985.^[7]

^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
^ US Patent 3845039
^ Mendels J (February 1994). "Evaluation of the safety and efficacy of quazepam for the treatment of insomnia in psychiatric outpatients". The Journal of Clinical Psychiatry. 55 (2): 60–65. PMID 7915708.
^ Yasui M, Kato A, Kanemasa T, Murata S, Nishitomi K, Koike K, et al. (June 2005). "[Pharmacological profiles of benzodiazepinergic hypnotics and correlations with receptor subtypes]". Nihon Shinkei Seishin Yakurigaku Zasshi = Japanese Journal of Psychopharmacology. 25 (3): 143–151. PMID 16045197.
^ Ongini E, Parravicini L, Bamonte F, Guzzon V, Iorio LC, Barnett A (1982). "Pharmacological studies with quazepam, a new benzodiazepine hypnotic". Arzneimittel-Forschung. 32 (11): 1456–1462. PMID 6129857.
^ Roth T, Tietz EI, Kramer M, Kaffeman M (1979). "The effect of a single dose of quazepam (Sch-16134) on the sleep of chronic insomniacs". The Journal of International Medical Research. 7 (6): 583–587. doi:10.1177/030006057900700620. PMID 42593. S2CID 36725411.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 538. ISBN 9783527607495.

[FDA-AllBoxedWarnings-1] "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

[2] US Patent 3845039

[3] Mendels J (February 1994). "Evaluation of the safety and efficacy of quazepam for the treatment of insomnia in psychiatric outpatients". The Journal of Clinical Psychiatry. 55 (2): 60–65. PMID 7915708.

[4] Yasui M, Kato A, Kanemasa T, Murata S, Nishitomi K, Koike K, et al. (June 2005). "[Pharmacological profiles of benzodiazepinergic hypnotics and correlations with receptor subtypes]". Nihon Shinkei Seishin Yakurigaku Zasshi = Japanese Journal of Psychopharmacology. 25 (3): 143–151. PMID 16045197.

[5] Ongini E, Parravicini L, Bamonte F, Guzzon V, Iorio LC, Barnett A (1982). "Pharmacological studies with quazepam, a new benzodiazepine hypnotic". Arzneimittel-Forschung. 32 (11): 1456–1462. PMID 6129857.

[6] Roth T, Tietz EI, Kramer M, Kaffeman M (1979). "The effect of a single dose of quazepam (Sch-16134) on the sleep of chronic insomniacs". The Journal of International Medical Research. 7 (6): 583–587. doi:10.1177/030006057900700620. PMID 42593. S2CID 36725411.

[Fis2006-7] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 538. ISBN 9783527607495.

[1]

[2]

[3]

[4]

[5]

[6]

[7]